The 7 analysts offering 12-month price forecasts for CTI Biopharma Corp have a median target of 10.00, with a high estimate of 15.00 and a low estimate of 7.90. The median estimate represents a +73.01% increase from the last price of 5.78.
The current consensus among 7 polled investment analysts is to Buy stock in CTI Biopharma Corp. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.15
Reporting Date Nov 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.